Connections between the frontal lobe and the basal ganglia: possible biomarkers for dopaminergic deviations

Completed

Conditions: geen
none

Registration Number: NL-OMON37920

Lead Sponsor: niversitair Medisch Centrum Utrecht

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Completed

Sex: Not specified

Target Recruitment: 40

Inclusion Criteria

Healthy subjects between age 18-50 years of age.

Exclusion Criteria

The following list of exclusion criteria is used:
- nonremovable metal objects in head/body
- pregnancy
- history of closed or open head injury
- history of psychiatric illness
- history of neurological illness or endocrinological dysfunction
- history of epilepsy
- occurrence of epilepsy in 1st degree family
- use of medication other than anticonceptive or paracetamol
- drug or alcohol abuse over a period of six months prior to the experiment
- intake of alcohol, caffeine or nicotine containing products within 4 hrs prior to the scanning sessions.
- claustrofobia

Study & Design

Study Type: Observational invasive

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>Four different measures reflecting our control over automatic reactions will be<br /><br>obtained during 4 visits:<br /><br><br /><br>1. striatal dopime levels inferred from lactate content using 1H-MRS<br /><br>2. functional MRI activation measurements in several regions of interest (ROI)<br /><br>3. effect of TMS on frontal cortex on oculomotor control<br /><br>4. average score per participant on several behavioral tests<br /><br><br /><br>A correlation analysis will determine whether inferred striatal dopamine levels<br /><br>per participant will correlate with measures 2-4. This outcome indicates<br /><br>whether striatal dopamine levels explain executive functioning and recruitment<br /><br>of areas in circuits involving the basal ganglia. When this is the case, the<br /><br>above measures are likely biomarkers for diseases affecting dopaminergic<br /><br>neurotransmission.</p><br>

Secondary Outcome Measures